To date, few cases of therapy‐related leukemia have been reported in long‐term follow‐up studies of BRCA1 and BRCA2 mutation carriers, but these studies have been limited by significant loss to follow‐up, a critical problem for identifying a toxicity that can occur up to 10 years later.17, 18, 19 Thus, longer term hematologic toxicity differences remain an open question and require further study. The gene discussed is BRCA2; the disease is leukemia.